Karyopharm Therapeutics (KPTI) Misses Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to Karyopharm Therapeutics (KPTI) Misses Q3 EPS by 1c

Karyopharm Therapeutics (KPTI) Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in PFSl in Patients with Unresectable Dedifferentiated Liposarcoma

November 2, 2020 4:03 PM EST

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced positive top-line results from the Phase 3 portion of the randomized, double blind, placebo controlled, cross-over, SEAL study evaluating single agent, oral XPOVIO® (selinexor) versus matching placebo in patients with advanced unresectable dedifferentiated liposarcoma. The SEAL study met its primary endpoint of a statistically significant increase in progression-free survival (PFS); hazard ratio=0.70; p=0.023. These data indicate that treatment with XPOVIO reduced the risk of disease progression or death by approximately 30%, compared to placebo. The trial allowed patients on placebo... More

Karyopharm Therapeutics (KPTI) Halted, News Pending

November 2, 2020 4:00 PM EST

Karyopharm Therapeutics (NASDAQ: KPTI) Halted, News Pending

... More